PP
ALDR

Paloma Partners’s Alder Biopharmaceuticals ALDR Stock Holding History

Paloma Partners’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-18,100
Closed -$286K – 2113
2018
Q2 		$286K Buy
+18,100
New +$275K 0.01% 1306
2018
Q1 		– Sell
-19,411
Closed -$222K – 2400
2017
Q4 		$222K Buy
+19,411
New +$217K ﹤0.01% 1688

Other funds holding ALDR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Paloma Partners's ALDR Position: Q3 2018 in Review

Paloma Partners sold out of Alder Biopharmaceuticals (ALDR) in Q3 2018, closing a stake of 18,100 shares — an estimated $286K sold.

Paloma Partners first reported a position in ALDR in Q4 2017 and held it in 2 quarters. The position peaked at $286K in Q2 2018. 127 funds tracked by Wall St. Rank hold ALDR as of Q3 2018.

  • Paloma Partners reported no remaining Alder Biopharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Paloma Partners sold 18,100 Alder Biopharmaceuticals shares in Q3 2018, an estimated $286K.
  • Paloma Partners first reported a position in Alder Biopharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Paloma Partners's Alder Biopharmaceuticals position peaked at $286K in Q2 2018.
  • 127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.